News Release

Printer Friendly Version View printer-friendly version
« Back
INSYS Therapeutics, Inc. to Participate in Oppenheimer Specialty Pharma Summit

PHOENIX, Oct. 09, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will participate in the Oppenheimer Specialty Pharma Summit to be held Oct. 11, 2017 at the Sofitel Hotel in New York.

Management will provide an overview of the company’s business in one-on-one meetings with investors who are registered to attend the conference. The presentation slides will be available during the conference and can be accessed by visiting the News & Events page of the Investors section of the company’s website at https://www.insysrx.com/.

About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS® (fentanyl sublingual spray), CII, and SYNDROS® (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.

SUBSYS® and SYNDROS® are trademarks of INSYS Development Company, Inc., a subsidiary of INSYS Therapeutics, Inc.

NOTE: All trademarks and registered trademarks are the property of their respective owners. 

CONTACT:

Media Relations
Joe McGrath
Senior Director, Corporate Communications
INSYS Therapeutics
480-500-3101
[email protected]

Investor Relations
Jackie Marcus or Chris Hodges
Alpha IR Group
312-445-2870
[email protected]

Primary Logo

Insys Therapeutics, Inc.